Chronic Rhinosinusitis with Nasal Polyps

Target Audience

The educational design of this activity addresses the needs of healthcare providers (HCPs) who manage patients with chronic rhinosinusitis with nasal polyps (CRSwNP), including allergy/clinical immunology, ear, nose and throat (ENT), and pulmonology clinicians.

Program Overview

Chronic inflammatory diseases of the upper and lower airways, especially CRSwNP and asthma, have been tied to significant risks and burdens for affected patients and frequently require close coordinated multidisciplinary care. Targeted agents designed to interrupt inflammatory cytokine signaling have been examined in clinical trials and evidence suggests these options can provide a range of benefits in patients with CRSwNP and related comorbidities. During this interactive activity, expert faculty will provide multidisciplinary insights related to diagnosis and management of patients with CRSwNP. Topics will include CRSwNP symptom presentation and diagnosis, overlapping pathophysiologic processes in chronic inflammatory airway diseases, the rationale and evidence behind biologic therapies, and integrated therapeutic strategies to achieve long-term global disease control. Please join our expert faculty and a patient with CRSwNP on this journey.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Describe CRSwNP pathogenesis and burdens, including implications for treatment planning
2. Comprehensively assess patients with CRSwNP for symptom burden, disease phenotypes, and effects on health-related quality of life
3. Describe the clinical profiles, recent trial data, and prescribing considerations for biologic treatment options in CRSwNP
4. Individualize treatment regimens for patients with CRSwNP based on symptoms, endotype, treatment goals, comorbidities, and shared clinical decision making

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score at least 75% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Flavia Hoyte, MD: Consulting Fees: AstraZeneca plc, Genentech, Sanofi-aventis U.S. LLC, Teva Pharmaceutical Industries Ltd., GSK; Contracted Research: Institution received research support from Genentech, Inc., Sanofi-aventis U.S. LLC, GSK plc; Fees for Non-CE Services Received Directly From an Ineligible Entity or Their Agents: AstraZeneca plc, Genentech; Stock Shareholder: Amgen

Stella Lee, MD: Consulting Fees: AstraZeneca plc, Genentech, GSK plc, Lyra Therapeutics, OptiNose, Sanofi Regeneron; Contracted Research: AstraZeneca plc, Genentech, GSK plc, Lyra Therapeutics, OptiNose, Sanofi Regeneron

The planners and managers have no following relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.